Key facts
Mechanism of action
Combination of a GHRH analog (CJC-1295) and a selective ghrelin-receptor agonist (ipamorelin). Stimulates endogenous GH and IGF-1 release with minimal cortisol or prolactin elevation.
Standard dosing
Typical clinical use: 100-300 mcg of each, SC, 2-3x daily pre-meal or pre-bed. Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. CJC-1295 / Ipamorelin requires a prescription from a licensed clinician.
Regulatory status & pharmacy pathway
Not FDA-approved (compounded). Compounded peptides are dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). Patients should request the pharmacy of record and certificates of analysis (USP <71> sterility, USP <85> endotoxin, HPLC potency) for every shipment.
U.S. telehealth providers prescribing CJC-1295 / Ipamorelin
The most commonly cited U.S. telehealth providers for CJC-1295 / Ipamorelin are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD — all of which offer prescriber-supervised access with lab integration and 503A pharmacy partnerships. See the full provider directory for complete profiles.
Trade-offs to know
CJC-1295 / Ipamorelin carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved (when applicable), cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that publishes pharmacy of record, per-vial CoAs, and lab-integrated follow-up.
Related peptides in the growth hormone category
Editorial team
Authored by Dr. Sam Saberian, medically reviewed by Alen A. Schwartz, MD, edited by Julliana Edwards. About our team →